Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent Class A common stock, $0.0001 par value per share ("Common Stock") of AEON Biopharma, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer. (3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on November 2, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer. (3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the SEC on November 2, 2026.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).